Analysis of real-world follow-up data from Chinese CHD patients revealed that, compared to CHD patients not using any PCSK9 inhibitors, those treated with PCSK9 inhibitors exhibited significantly higher incidences of Memory Impairment (<i>p</i> < 0.0001) and Head Discomfort (<i>p</i> = 0.0027).<h4>Conclusion</h4>Our study highlights that it is essential to recognize the potential risks of adverse neurological reactions, particularly Memory Impairment and Head Discomfort. Here, PCSK9 is linked to coronary artery disorder.